linjc16/ctgov huggingface dataset:
Erector Spinae Plane Block Versus Quadratus Lumborum Block For Postoperative Analgesia After Abdominal Hysterectomy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the analgesic efficacy of erector spinae plane block and quadratus lumborum block after abdominal hysterectomy surgery and postoperative opioid consumption.

Official Title
-----------------
Erector Spinae Plane Block Versus Quadratus Lumborum Block For Postoperative Analgesia After Abdominal Hysterectomy; A Randomized Comparative Study

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Procedure: peripheral nerve block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with American Society of Anesthesiologists (ASA) physical status 1-3. scheduled for abdominal hysterectomy surgery. Exclusion Criteria: History of allergy to the medications used in the study. Contraindication to regional anesthesia as coagulopathy, local infection. Severe hepatic impairment (child C). Sever Renal dysfunction (creatinine clearance < 30). Psychiatric or mental disorder affecting patient ability to interpret VAS score. Body mass index (BMI) ≥ 40 or ≤ 18 kg/m2. ASA IV. Patient refusal.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ESPB<br>Erector Spinae Plane Block group | Procedure: peripheral nerve block<br>* ultrasound guided nerve block<br>|
| Active Comparator: QLB<br>Quadratus Lumborum Block group | Procedure: peripheral nerve block<br>* ultrasound guided nerve block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative pain | Post-operative pain severity assessed by visual analog scale (VAS) (range from 0-10., 0 no pain, 10 worst pain ). | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative post-operative opioid consumption | opioid consumption | 24 hours | 
| The onset of 1st analgesic request | time needed for 1st request of rescue analgesia | 24 hours |
Phenylephrine Versus Norepinephrine in Septic Shock

Study Overview
=================
Brief Summary
-----------------
Clinical studies evaluating the clinical use of phenylephrine in septic shock are lacking. The present study was designed to compare the effects of norepinephrine and phenylephrine on systemic and regional hemodynamics in patients with catecholamine-dependent septic shock.

Official Title
-----------------
Effects of Phenylephrine on Systemic and Regional Hemodynamics in Patients With Septic Shock: a Crossover Pilot Study

Conditions
-----------------
Septic Shock

Intervention / Treatment
-----------------
* Drug: Phenylephrine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clical diagnosis of Septic Shock norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 12-18 mmHg and central venous pressure = 8-12 mmHg). Exclusion Criteria: Age < 18 years Pregnancy Present or suspected acute coronary artery disease Present or suspected acute mesenteric ischemia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Phenylephrine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic and regional hemodynamics |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Organ functions, adverse effects |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Septic shock, Sepsis, Norepinephrine, Phenylephrine
Lung Cancer Risk and Early Detection in Firefighters

Study Overview
=================
Brief Summary
-----------------
This study will evaluate whether LDCT findings differ between firefighters and non-fighters, the relationship between occupational exposures and LDCT findings, and whether a proteomics assay can further risk-stratify screen-detected nodules among a study population of 850 current and retired firefighters and 1,120 matched controls.

Official Title
-----------------
Lung Cancer Risk and Early Detection in Firefighters

Conditions
-----------------
Lung Cancer, Lung Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Low Dose CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40-80 years of age or with 10 years of firefighting experience Current or retired firefighters No personal history of lung cancer Willing and able to receive LDCT screening at MGH or who have been screened via LDCT within the past year at MGH or another institution, and are willing to release their images to the study Exclusion Criteria: Any active cancer (undergoing treatment or diagnosed within the past 5 years)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low-Dose CT<br>Low Dose CT Scan of the Chest | Diagnostic Test: Low Dose CT<br>* All participants will have a low dose chest CT either within one year of enrollment or after enrollment<br>* Other names: LDCT;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nodule detection rate | Frequency of nodule detection | 12 months | 
| High-risk nodule detection rate | Frequency of high-risk nodule detection. High risk is defined as a Lung RADS of 3 or 4. Lung RADS categories are as follows: 0) Incomplete; 1) Negative; 2) Benign appearance or behavior; 3) Probably benign; 4) Suspicious | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interstitial lung disease detection rate | Frequency of interstitial lung disease detection | 12 months | 
| Coronary artery calcification (CAC) ordinal scores | Frequency of high coronary artery calcification (CAC) ordinal scores. Possible scores range from 0 to 12 and high scores are defined as those greater than or equal to 10 | 12 months |
A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
To test whether Parcopa, a new Orally Disintegrating Tablet of Carbidopa-Levodopa, has a faster onset of action, changes in the UPDRS Motor Exam score at intervals after a single dose of Parcopa or Sinemet are being compared in 10 subjects with Parkinson's disease. Subjects 40 years or older having idiopathic PD with Hoehn and Yahr state II or III are eligible if taking a stable dose of < 200 mg carbidopa and < 2000 mg levodopa daily. At both treatment visits, either Parcopa or Sinemet, plus a placebo of the opposite tablet (ODT or conventional) are administered. The dose is the same as the subject's prestudy regimen. The primary efficacy variable, time to onset of action, is the first postdose time when a 30% decrease (30% improvement) in the total score is achieved. All UPDRS evaluations are done by a rater blinded to the active treatment received by the subject.

Detailed Description
-----------------
See approved Package Insert for Adverse Event information.

Official Title
-----------------
A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: Parcopa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable Parkinson's disease Exclusion Criteria: idiopathic PD with Hoehn and Yahr state II or III

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Parcopa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine choice of anticoagulant therapy during acute and chronic stages of ischemic stroke/TIA and short- and long-term outcomes, including stroke recurrence and bleeding complications, in patients having nonvalvular atrial fibrillation.

Official Title
-----------------
Stroke Acute Management With Urgent Risk-factor Assessment and Improvement (SAMURAI) Study on Anticoagulant Therapy in Nonvalvular Atrial Fibrillation (NVAF)

Conditions
-----------------
Stroke, Acute, Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: This is an observational study.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive acute ischemic stroke/TIA patients with NVAF Exclusion Criteria: Rheumatic mitral valve disease A history of prosthetic valve replacement or mitral valve surgical repair Active infective endocarditis Patient, family member or legally responsible person does not have given informed consent Inappropriate patient's conditions for study enrollment in the opinion of the investigator
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NVAF, acute ischemic stroke/TIA<br>Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention | Other: This is an observational study.<br>* This is an observational, not intervention, study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ischemic events | Recurrence of ischemic stroke/TIA, ACS, systemic embolism, aortic dissection, rupture of aortic aneurysm, peripheral artery disease (required hospitalization), VTE, revascularization (including CEA/CAS, PCI, etc) | 2 years | 
| major bleeding | Major bleeding according to the ISTH definition, including fatal bleeding, intracranial hemorrhage, etc | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| modified Rankin Scale | modified Rankin Scale | 2 years | 
| Modification of anticoagulant medication |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anticoagulation, Recurrent stroke, Bleeding
Acupuncture for the Treatment of Vulvodynia

Study Overview
=================
Brief Summary
-----------------
A randomized controlled pilot study was conducted to evaluate the effect of an acupuncture protocol for the treatment of vulvodynia. Hypotheses: Acupuncture reduces vulvar pain and dyspareunia in women with vulvodynia. Acupuncture increases sexual function in women with vulvodynia.

Official Title
-----------------
Acupuncture for the Treatment of Vulvodynia

Conditions
-----------------
Vulvodynia, Vulvar Vestibulitis, Pain, Dyspareunia, Female Sexual Dysfunction Due to Physical Condition

Intervention / Treatment
-----------------
* Other: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously diagnosed with either generalized vulvodynia, localized vestibulodynia, or both Provoked vulvodynia Unprovoked vulvodynia Women between 18 years of age and menopause Exclusion Criteria: Pregnancy Menopause Interstitial cystitis Irritable bowel syndrome Untreated vaginitis Cervicitis Pelvic inflammatory disease Diagnosed with other pelvic pathology causing pain Concomitantly receiving physical therapy Concomitantly receiving biofeedback, Concomitantly receiving massage Concomitantly receiving additional acupuncture.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acupuncture<br>Acupuncture | Other: Acupuncture<br> <br> |
| No Intervention: Wait-list Control<br>Wait-list Control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vulvar pain | Change from baseline in The Short Form McGill Pain Questionnaire at 5 weeks | Baseline and 5 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspareunia | Change from baseline in the pain subscale of the Female Sexual Function Index at 5 weeks | Baseline and 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vulvodynia, Acupuncture, Provoked Vestibulodynia, Vulvar Vestibulitis, Vulvar Pain, Dyspareunia, Female Sexual Function
Temperature Measurement in Post-Anesthesia Care Units

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the accuracy of several thermometers and temperature changes during surgery and immediately after surgery.

Detailed Description
-----------------
Several measurements of temperature will be taken at 30 minute intervals during surgery under general anesthesia and in the post operative care unit. Measurements will be taken as follows: esophagus using an internal stethoscope urinary bladder using a catheter ear canal skin of the forehead using adhesive devices(4 thermometers) axilla (armpit) using adhesive devices(2 thermometers) mouth skin of the upper chest

Official Title
-----------------
Accuracy of Temperature Measurement in Post-Anesthesia Care Units

Conditions
-----------------
Surgery, Postoperative, Laparoscopic Surgery, General Anesthesia

Intervention / Treatment
-----------------
* Device: Body temperature thermometers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 80 years of age American Society of Anesthesiologists (ASA) physical status of 1-3 laparoscopic surgery of the abdomen or pelvis that is expected to require general endotracheal anesthesia and insertion of a Foley catheter expected to be in place for at least one hour after surgery Exclusion Criteria: under 18 or over 80 years of age pre-existing nasogastric tube require bispectral index monitoring upper esophageal disease forehead rash or infection, oral infection or trauma, or ear infection or drainage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| observation group<br>Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter. | Device: Body temperature thermometers<br>* Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.<br>* Other names: 11. Deep temperature with a 7-cm probe over the subclavicular region of the upper chest;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the accuracy of various temperature-monitoring methods and sites suitable for Post Anesthesia Care Unit use. |  | Discharge from Post Anesthesia Care Unit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To quantify the core temperature changes that occur during transport from the Operating Room to the PostAnesthesia Care Unit. |  | PostAnesthesia Care Unit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
temperature, monitor, surgery
A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the incidence rate of Candida blood stream infection (candidemia) among people hospitalized in participating medical centers in Brazil, and will assess the antifungal drug susceptibility patterns of Candida clinical isolates. No hypotheses will be tested in the study. Candida blood stream isolates collected from people hospitalized for any reason during the study period will be sent to a core mycology laboratory for antifungal drug susceptibility testing. All people who develop candidemia while hospitalized will be considered participants in the study.

Official Title
-----------------
Brazilian Network of Candidemia: a Laboratory-based Surveillance Study on Candida Bloodstream Infections in 10 Medical Centers

Conditions
-----------------
Candidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized in a participating medical center Developed candidemia blood stream infection (confirmed by isolation of Candida species from blood culture)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hospital Candida Cases<br>People who developed a positive blood culture for Candida while hospitalized | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with Candidemia per 1000 hospital admissions | A candidemia case was defined as the first isolation of any Candida species from blood within a 30-day period during hospitalization. The incidence of candidemia was calculated as (number of participants / [number of total people hospitalized during the study period / 1000]) | Approximately 1 year | 
| Number of participants with Candidemia per 1000 patient-Days in hospital | A candidemia case was defined as the first isolation of any Candida species from blood within a 30-day period during hospitalization. The incidence of candidemia was calculated as (number of participants / [number of total patient-days of hospitalization during the study period / 1000]). | Approximately 1 year | 
| Percentage of Specific Candida Isolates Susceptible to Amphotericin B, Fluconazole, Voriconazole, Anidulafungin, and Caspofungin | Candida bloodstream isolates were tested for susceptibility to antifungal drugs using the Clinical and Laboratory Standards Institute (CLSI) microbroth dilution method with final readings recorded after 24 hours. The susceptibility cutoffs for antifungal drugs except amphotericin B were from the CLSI M27-S4 Reference Supplement (December 2012). The susceptibility cutoff for amphotericin B was obtained from the published literature. | Approximately 1 year |
Systems of Underprivileged Preschoolers in Their Home and Preschool EnviRonment: Family Intervention Trial

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the effectiveness of SuperFIT, an integrative lifestyle intervention for preschool children. It will consist of both an preschool component and a family component and is aimed at increasing healthy nutrition and physical activity. Half of the participating preschools will implement SuperFIT, while the other half of the preschools will continue as usual.

Official Title
-----------------
Development and Evaluation of SuperFIT: Systems of Underprivileged Preschoolers in Their Home and Preschool EnviRonment: Family Intervention Trial.

Conditions
-----------------
Child Obesity

Intervention / Treatment
-----------------
* Behavioral: SuperFIT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children attending the participating preschools at least one parent has to be able to understand the Dutch language Both caregivers (if applicable) of the child give informed consent Exclusion Criteria: There are no exclusion criteria for this study

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SuperFIT<br>This is the intervention group. They will receive the intervention SuperFIT. | Behavioral: SuperFIT<br>* Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.<br>|
| No Intervention: Control<br>This is the control group. Participants will receive 'care as usual' in this arm. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in BMI |  | from baseline to one year and 1.5 years after baseline | 
| Change in physical activity by an Actigraph accelerometer |  | from baseline to one year and 1.5 years after baseline | 
| Change in Diet, Food and Nutrition by a 24HR recall |  | from baseline to one year and 1.5 years after baseline |